In a patient who experienced mild itching of the hands and feet during iron sucrose infusion and, 24 hours later, presents with hemolysis, sub‑KDIGO acute kidney injury, proteinuria, and hematuria, how supportive is this of a complement‑mediated disorder such as atypical hemolytic‑uremic syndrome?

Clinical Presentation is Moderately Supportive of Complement-Mediated Disorder but Requires Urgent Diagnostic Workup

This clinical scenario raises significant concern for atypical hemolytic uremic syndrome (aHUS) or another complement-mediated thrombotic microangiopathy (TMA), and you should proceed immediately with diagnostic testing while preparing for potential complement blockade therapy. The combination of hemolysis, renal involvement (proteinuria and hematuria), and a potential triggering event (iron infusion with reaction) occurring within 24 hours creates a clinical picture that warrants urgent evaluation for complement-mediated disease 1.

Why This Presentation Raises Concern

The key supportive features include:

• Hemolysis with renal involvement: The triad of microangiopathic hemolytic anemia, thrombocytopenia (if present), and acute kidney injury characterizes aHUS 1. Your patient demonstrates hemolysis plus renal stress (proteinuria and hematuria), which are two of the three cardinal features.

• Temporal relationship to a trigger: Iron sucrose infusion with a mild reaction could represent a triggering event. aHUS is frequently precipitated by infections, medications, or other stressors 1. The 24-hour timeline between exposure and symptom onset is consistent with complement-mediated injury.

• Incomplete triad does not exclude aHUS: Critically, in almost 50% of cases at onset, not all three clinical signs (hemolytic anemia, thrombocytopenia, renal involvement) are clearly present 1. The absence of marked thrombocytopenia should not exclude TMA from your differential 1.

Critical Immediate Actions

1. Confirm Hemolysis and TMA Features

Obtain these laboratory tests urgently 1:

• Direct Coombs test (must be negative for aHUS diagnosis)
• LDH, haptoglobin, indirect bilirubin (elevated LDH, reduced/absent haptoglobin confirm hemolysis)
• Peripheral blood smear for schistocytes (>1% supports TMA, but absence does not exclude it due to low sensitivity 1)
• Complete blood count (assess for thrombocytopenia - platelets <150,000/mm³ or 25% reduction)
• Creatinine and urinalysis (you already have proteinuria and hematuria)

2. Exclude Alternative Diagnoses

ADAMTS13 activity must be obtained as an urgent test 1:

• If <10 IU/dL, this indicates thrombotic thrombocytopenic purpura (TTP), not aHUS
• Normal ADAMTS13 supports aHUS diagnosis

Additional exclusions:

• Stool culture for Shiga toxin-producing E. coli (STEC) 1
• Pregnancy test (if applicable)
• Complement levels (C3, C4) and anti-factor H antibodies (though normal levels do not exclude aHUS 2)

3. Assess for Subclinical Presentation

The clinician can rely on the combined use of: (i) clinical presentation; (ii) laboratory data suggestive of hemolysis; (iii) appearance/increase of glomerular proteinuria; and (iv) appearance of microhematuria 1. Your patient demonstrates all four of these features.

The Iron Sucrose Connection

The FDA label for iron sucrose warns of serious hypersensitivity reactions, including anaphylactic-type reactions 3, but does not specifically link iron sucrose to complement activation or hemolysis. However:

• The mild itching reaction during infusion could represent either:

  1. A hypersensitivity reaction (most likely given FDA warnings 3)
  2. A triggering event that unmasked underlying complement dysregulation in a predisposed individual

• Factors that trigger aHUS include certain medications, infections, and other stressors 1. While iron sucrose is not classically listed as an aHUS trigger, any inflammatory or immune stimulus can precipitate complement-mediated TMA in susceptible patients.

Important Caveats and Pitfalls

Pitfall #1: Waiting for Complete Triad

Do not wait for all three features (hemolysis, thrombocytopenia, AKI) to be fully manifest before acting 1. aHUS frequently presents incompletely, and delays in treatment are associated with increased morbidity and mortality 1.

Pitfall #2: Alternative Hemolysis Mechanism

Consider that hemoglobinuria-induced acute tubular injury could explain the renal findings without TMA 2. If hematologic parameters improve but renal dysfunction persists, kidney biopsy should be performed when feasible to distinguish TMA from pigment nephropathy 2.

Pitfall #3: Genetic Testing Limitations

The absence of mutations or known antibodies cannot exclude the involvement of complement dysregulation 1. Only 60% of aHUS cases have identifiable genetic mutations 1, 4.

Treatment Decision Algorithm

If diagnostic workup confirms:

• Non-immune hemolytic anemia (negative Coombs)
• Normal ADAMTS13 activity
• No STEC infection
• Progressive or persistent hemolysis with renal involvement

Then initiate complement blockade therapy (eculizumab or ravulizumab) within 4-8 hours of diagnosis 1. Delays are associated with increased morbidity and mortality. Eculizumab has demonstrated superior outcomes compared to plasma exchange in dialysis-dependent aHUS patients, with 80% achieving complete kidney function recovery versus 38.5% with plasma exchange alone 5.

Before initiating complement blockade:

• Administer meningococcal vaccines (quadrivalent A, C, W, Y and serogroup B)
• Start antimicrobial prophylaxis with penicillin (or macrolide if allergic) 1

Bottom Line Assessment

This presentation is moderately-to-highly supportive of complement-mediated disease given the temporal relationship, hemolysis, and renal involvement in a patient with suspected subclinical complement dysregulation. The iron sucrose infusion likely acted as a triggering event rather than a direct cause. However, you must urgently complete the diagnostic workup outlined above to confirm TMA, exclude TTP and STEC-HUS, and determine whether complement blockade is indicated. Do not delay diagnostic testing or treatment initiation if clinical suspicion is high, as aHUS is a life-threatening emergency 1, 5.